Long-term follow-up of a phase 2 study of all-trans retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin in acute promyelocytic leukemia. - Jen WY; Marvin-Peek J; Kantarjian HM; Alvarado Y; Borthakur G; Jabbour E; Wierda W; Kadia TM; Daver NG; DiNardo CD; Short NJ; Jain N; et al. (Cancer, 2025)